NP-160 (Bromantane)

About NP-160 (Bromantane) 

The Company’s lead drug for chronic kidney disease (CKD) is  Bromantane (NP-160). It is representative of a class of drugs called “actoprotectors” developed during the Soviet Union era to improve performance of their military, cosmonauts and national athletes under extreme physical conditions.

NP-160 (Bromantane: N-2-adamantil-N-(para-bromophenyl-amine) was also developed in the Soviet Union in the 1980s and has been manufactured in Russia (commercial name: Ladasten) since 1997. Most recently the drug was manufactured by Pharmstandard, a large Russian domestic pharmaceutical company, until the end of 2018. Similar to NP-135 (Bemethyl), NP-160 (Bromantane), also improved performance under extreme conditions and was later repurposed as a more general treatment for neurasthenia. The drug is currently on the WADA list of banned substances.

Data

NP-160 (40 mg/kg) reduced fibrosis by 57.6% (p<0.000001). NP-160 was also previously reported to be anti-fibrotic in a mouse model of non-alcoholic steatohepatitis (NASH).

  • Telmisartan (3mg/kg), a positive control, reduced fibrosis by 32.6% (p<0.001).
  • Cenicriviroc (40 mg/kg) a CCR2/5 chemokine receptor antagonist with reported anti-fibrotic activity, reduced fibrosis by 31.9% (p=0.00032).
  • NP-160 (40 mg/kg) reduced fibrosis by 57.6% (p <0.000001). NP-160 was also previously reported to be anti-fibrotic in a mouse model of non-alcoholic steatohepatitis (NASH).